Matthew Ku

University of Melbourne

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Collaborators (3)

Chan Yoon Cheah

University of Western Australia

Eliza Hawkes

Associate Professor

MONASH UNIVERSITY

Katharine Lewis

University of Western Australia

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Matthew Ku

Research Interests

Explore related searches

Contact this professor

Articles (20)

Collaborators (3)

Chan Yoon Cheah

Eliza Hawkes

Katharine Lewis

Make your next move.

Matthew Ku

Research Interests

Explore related searches

Contact this professor

Articles (20)

ABCL-544: Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): 2 Year Follow-Up of the Phase 3 STARGLO Trial

POSTER: ABCL-544 Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): 2 Year Follow-Up of the Phase 3 STARGLO Trial

Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study

104 | A GLOBAL PHASE 1B STUDY OF JNJ‐90014496, A CD19/CD20 BI‐SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T‐CELL THERAPY, IN RELAPSED/REFRACTORY (R/R) LARGE B‐CELL LYMPHOMA (LBCL)

23 | RADIOTHERAPY IMPROVES PROGRESSION‐FREE SURVIVAL FOR STAGE IA NLPHL: A RETROSPECTIVE REPORT FROM THE GLOBAL NLPHL ONE WORKING GROUP (GLOW)

236 | MOSUNETUZUMAB DEMONSTRATES DURABLE CLINICAL BENEFIT IN PATIENTS WITH COMPLETE RESPONSE AND HIGH‐RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

296 | LIMITED STAGE DIFFUSE LARGE B CELL LYMPHOMA IN THE MODERN ERA: REAL‐WORLD OUTCOMES IN AN INTERNATIONAL STUDY OF OVER ONE THOUSAND PATIENTS

59 | CLONAL HEMATOPOIESIS IS ASSOCIATED WITH PERSISTING ANEMIA IN ELDERLY PATIENTS TREATED FOR DLBCL: ANALYSIS OF THE PHASE 3 POLAR BEAR TRIAL

76 | GLOFITAMAB PLUS GEMCITABINE AND OXALIPLATIN (Glofit‐GemOx) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): 2‐YEAR FOLLOW‐UP OF STARGLO

830 | A PHASE 1 STUDY EVALUATING SAFETY, PHARMACOKINETICS, AND EFFICACY OF ABBV‐291, A CD79B‐TARGETING ADC IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA

Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma.

IBCL-458 Mosunetuzumab Monotherapy Demonstrates Durable Efficacy With a Manageable Safety Profile in Patients With Relapsed/Refractory Follicular Lymphoma who Received ≥2 Prior Therapies: Updated Results From a Pivotal Phase II Study

POSTER: IBCL-458 Mosunetuzumab Monotherapy Demonstrates Durable Efficacy With a Manageable Safety Profile in Patients With Relapsed/Refractory Follicular Lymphoma who Received ≥2 Prior Therapies: Updated Results From a Pivotal Phase II Study

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma

Glofitamab plus R‐CHOP or polatuzumab vedotin‐R‐CHP is deliverable with high overall response in patients ≤65 years of age with high‐risk DLBCL: Interim analysis of COALITION

MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY

Outcomes of human immunodeficiency virus-associated Burkitt lymphoma and diffuse large B-cell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance

POLATUZUMAB, BENDAMUSTINE &amp; RITUXIMAB EFFICACY IN RELAPSED/REFRACTORY TRIAL‐INELIGIBLE LARGE B CELL LYMPHOMA PATIENTS: AN AUSTRALIAN LYMPHOMA REGISTRY (LARDR) STUDY

Characteristics and Outcomes of Older Patients With Classical Hodgkin Lymphoma: An Australasian Lymphoma Alliance, and Lymphoma and Related Diseases Registry Study

Abstract CT052: A phase 1/2 randomized study of imvotamab monotherapy and in combination with loncastuximab tesirine in relapsed/refractory non-Hodgkin lymphomas

Collaborators (3)

Chan Yoon Cheah

Eliza Hawkes

Katharine Lewis

Make your next move.

POLATUZUMAB, BENDAMUSTINE & RITUXIMAB EFFICACY IN RELAPSED/REFRACTORY TRIAL‐INELIGIBLE LARGE B CELL LYMPHOMA PATIENTS: AN AUSTRALIAN LYMPHOMA REGISTRY (LARDR) STUDY